|Cat. No. :
|Product Overview :
||Recombinant human VEGI-192 produced inE. coliis a single, non-glycosylated polypeptide chain containing 192 amino acids and having a molecular mass of 21.858 kDa.
||Vascular endothelial growth inhibitor (VEGI; TNFSF-15) is a new member of the tumor necrosis factor family. VEGI is predominantly an endothelial cell-specific gene, and recombinant VEGI is a potent inhibitor of endothelial cell proliferation, angiogenesis and tumor growth. VEGI exerts two activities on endothelial cells: early G1 arrest of G0/G1-cells responding to growth stimuli, and programmed death of proliferating cells. These activities are highly specific to endothelial cells. VEGI is also able to regulate the expression of several important genes involved in angiogenesis. These findings are consistent with the view that VEGI functions as an autocrine cytokine to inhibit angiogenesis and stabilize the vasculature.
||>95% by SDS-PAGE and RP-HPLC.
||Lyophilized after extensive dialysis against 0.5M NaCl, 50mM Tris-HCl buffer, pH 7.5.
|Specific Activity :
||The ED50 as determined by the dose-dependant inhibition of the proliferation of HUVEC (Human Umbilical Vein Endothelial Cells) is less than 5μg/ml.
||Less than 0.1 ng/µg (1 IEU/µg) of rHuVEGI
||It is recommended to reconstitute the lyophilized VEGI-192 in sterile 18MΩ-cm H2O not less than 100µg/ml, which can then be further diluted to other aqueous solutions.
||Lyophilized VEGI-192 although stable at room temperature for 3 weeks, should be stored desiccated below -18°C. Upon reconstitution VEGI-192 should be stored at 4°C between 2-7 days and for future use below -18°C. For long-term storage it is recommended to add a carrier protein (0.1% HSA or BSA). Aliquot to avoid repeated freeze-thaw cycles.